EXORPHIA

EXORPHIA is a Tokyo-based biotechnology company specializing in the development of next-generation therapeutics and medical products using extracellular vesicles (EVs), also known as exosomes. The company leverages its proprietary INPACT-EV™ and Prime-EV® platforms to manufacture high-activity and engineered EVs for a variety of applications. Its lead program, EXP02, is an acellular IVF culture media supplement derived from umbilical cord cells, aimed at improving embryo development and quality in assisted reproductive technology. Beyond fertility, EXORPHIA is advancing a pipeline of EV-based treatments for inflammatory conditions like ARDS and atopic dermatitis, as well as an intranasal vaccine platform. The company has established strategic partnerships with Rohto Pharmaceutical and Kyoritsu Seiyaku to expand its reach into human and veterinary medicine.